two
diagnost
bundl
compar
evalu
patient
admit
communityacquir
pneumonia
cap
diagnost
modal
patient
includ
cultur
sputum
obtain
blood
urin
detect
antigen
streptococcu
pneumonia
legionella
pneumophila
nasal
swab
pcr
probe
pneumonia
staphylococcu
aureu
least
one
procalcitonin
level
measur
patient
viru
detect
patient
random
either
labgener
pcr
panel
broader
faster
filmarray
pcr
panel
overal
etiolog
diagnosi
establish
patient
respiratori
viru
detect
potenti
improv
antibiot
stewardship
evid
patient
detect
respiratori
viru
normal
level
pct
communityacquir
pneumonia
cap
common
potenti
lethal
infecti
diseas
requir
concomit
attempt
determin
microbi
etiolog
prompt
initi
broad
spectrum
empir
antibacteri
mandel
et
al
studi
design
optim
rapid
detect
pathogen
bacteria
andor
virus
use
normal
serum
procalcitonin
pct
level
exclud
presenc
invas
bacteria
provid
microbiolog
pct
data
clinician
within
hour
less
admiss
determin
physician
provid
would
respond
data
provid
switch
empir
either
therapi
noninfluenza
viral
ill
direct
specif
antimicrobi
regimen
protocol
describ
herein
use
januari
march
gelfer
et
al
enrol
addit
patient
winter
month
studi
conduct
nonblind
cluster
random
trial
bed
communityteach
hospit
portland
oregon
provid
portland
medic
centerppmc
project
approv
institut
review
board
irb
privaci
board
ppmc
deidentifi
chart
data
collect
irb
indic
need
inform
consent
prior
studi
initi
investig
review
studi
protocol
emerg
depart
nurs
physician
hospitalist
resid
clerk
diagnosi
cap
requir
admiss
made
ed
physician
prompt
enrol
studi
ed
physician
order
protocolmand
diagnost
bundl
initi
ed
nurs
also
order
empir
antibiot
therapi
ed
unit
clerk
notifi
investig
new
patient
protocol
neither
dictat
suggest
antibiot
manag
either
ed
inpati
physician
provid
learn
test
result
via
electron
medic
record
emr
two
except
provid
notifi
immedi
posit
blood
cultur
identif
influenza
common
core
diagnost
test
appli
patient
studi
ie
two
blood
cultur
sputum
cultur
sensit
serum
pct
level
urin
antigen
test
legionella
pneumophila
serogroup
streptococcu
pneumonia
nasal
swab
pcr
detect
lyt
gene
pneumonia
staphylococcu
aureu
aureu
pcr
bd
max
staph
sr
purchas
bectondickinson
pct
level
determin
use
immunoassay
biomerieux
perform
vida
system
protocol
call
one
baselin
pct
serum
level
provid
order
addit
pct
level
discret
pct
result
includ
interpret
algorithm
model
widelyus
use
european
format
schuetz
et
al
schuetz
et
al
valu
ngml
interpret
bacteri
etiolog
unlik
valu
ngml
bacteri
etiolog
like
valu
ngml
bacteri
etiolog
like
algorithm
suggest
diagnost
microbiolog
infecti
diseas
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
g
c
r
b
repeat
pct
level
hour
patient
level
ngml
possibl
evolv
bacteri
infect
addit
common
bundl
patient
clusterrandom
one
week
block
undergo
addit
diagnost
test
either
ppmc
laboratorygener
respiratori
pathogen
pcr
panel
standard
commerci
multiplex
pcr
panel
filmarray
biofir
salt
lake
citi
ut
standard
panel
probe
influenza
b
adenoviru
human
metapneumoviru
respiratori
syncyti
viru
rhinoviru
specimen
run
daili
least
day
per
week
result
avail
within
hour
altern
week
nasaopharyng
np
swab
process
filmarray
probe
five
type
influenza
four
type
parainfluenza
rhinoviru
enteroviru
adenoviru
human
metapneumoviru
four
type
coronaviru
respiratori
syncyti
viru
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
author
extract
data
patient
emr
use
assign
studi
number
databas
file
filemak
pro
data
extract
began
enrol
continu
period
hospit
complet
postdischarg
data
entri
verifi
two
three
author
infecti
diseas
pharmacist
enter
data
refer
use
antibacteri
andor
antiinfluenza
therapi
use
standard
list
purchas
expens
individu
antibiot
one
investig
dng
determin
day
expens
antimicrobi
therapi
given
day
empir
therapi
differ
antibiot
regardless
number
dose
defin
day
therapi
dot
length
number
day
therapi
lot
regardless
number
drug
administ
day
also
calcul
result
normal
hospit
patientday
inclus
requir
ed
diagnosi
cap
suffici
sever
requir
hospit
patient
year
age
older
patient
exclud
possibl
obtain
np
swab
antibiot
withheld
comfort
care
initi
postenrol
patient
exclud
two
site
infect
present
eg
cap
plu
noncap
infect
patient
place
comfort
care
discontinu
antiinfect
failur
collect
protocolmand
diagnost
test
patient
unabl
provid
accept
sputum
cultur
exclud
final
databas
enrol
patient
review
two
investig
jl
dng
purpos
final
categor
per
definit
event
disagr
adjud
third
investig
gg
criteria
assign
final
clinic
diagnosi
uninfect
evid
cap
postadmiss
clinic
laboratori
imag
studi
document
altern
noninfecti
diagnosi
eg
congest
heart
failur
proven
pulmonari
infiltr
bacteri
pathogen
sputum
blood
pleural
fluid
posit
pneumonia
np
swab
pcr
andor
pneumonia
urin
antigen
accept
bacteri
pneumonia
presumpt
multifoc
pulmonari
infiltr
detect
pneumonia
aureu
pcr
nasal
swab
patient
possibl
obtain
sputum
bronchoalveolar
lavag
specimen
elev
serum
procalcitonin
use
evid
bacteri
invas
oppos
asymptomat
colon
presenc
clinic
pneumonia
serum
procalcitonin
level
ngml
accept
presumpt
evid
bacteri
pneumonia
absenc
detect
bacteri
pathogen
eg
patient
document
aspir
presumpt
identif
presenc
adenoviru
coronaviru
human
metapneumoviru
influenza
parainfluenza
respiratori
syncyti
viru
rhinoviru
one
pcr
probe
compat
clinic
syndrom
distinct
potenti
bacteri
pathogen
like
aureu
pneumonia
asymptomat
nasal
colon
respiratori
viral
pathogen
rare
occurr
presumpt
respiratori
viru
detect
either
serum
pct
ngml
andor
bacteri
pathogen
found
sputum
cultur
urin
antigen
pcr
bacteri
viral
pathogen
identifi
potenti
etiolog
agent
seroconvers
studi
perform
patient
file
review
three
investig
gg
jl
dg
patient
consid
evalu
protocolrequir
diagnost
studi
perform
except
sputum
cultur
sputum
could
obtain
patient
file
review
determin
patient
pneumonia
diagnosi
hindsight
correct
patient
clinic
pneumonia
syndrom
investig
classifi
etiolog
pneumonia
one
way
viral
bacteri
combin
viral
bacteri
pathogen
found
clinic
pneumonia
unclear
etiolog
respiratori
viru
detect
associ
bacteri
infect
deem
present
bacteri
pathogen
identifi
cultur
pcr
urin
antigen
serum
pct
concentr
ngml
comparison
two
diagnost
method
test
wilcoxon
test
perform
continu
variabl
chisquar
test
fisher
exact
test
perform
categor
variabl
kruskalw
test
oneway
anova
test
use
comparison
among
three
distinct
etiolog
group
viral
bacteri
combin
viral
bacteri
decemb
march
ed
admit
patient
diagnosi
cap
fig
patient
random
standard
group
patient
nonevalu
due
inadequ
evid
pneumonia
incomplet
diagnost
transit
comfort
care
within
day
patient
inadequ
evid
pneumonia
attribut
patient
bronchiti
copd
exacerb
sepsi
anoth
sourc
chf
cystic
fibrosi
metastat
cancer
mai
chemic
aspir
remain
evalu
patient
pathogen
identifi
patient
random
filmarray
group
patient
nonevalu
due
inadequ
evid
pneumonia
incomplet
diagnost
transit
comfort
care
patient
within
day
inadequ
evid
pneumonia
attribut
patient
bronchiti
copd
exacerb
sepsi
anoth
sourc
chf
metastat
cancer
asthma
pulmonari
embol
chemic
aspir
remain
evalu
patient
pathogen
identifi
nonevalu
patient
otherwis
similar
evalu
respect
demograph
comorbid
featur
list
tabl
demograph
clinic
featur
standard
filmarray
evalu
patient
summar
tabl
pneumonia
sever
index
psi
rang
result
similar
place
bulk
patient
risk
group
iii
score
henc
justifi
hospit
comorbid
evenli
distribut
combin
evalu
patient
standard
filmarray
group
one
potenti
pathogen
detect
patient
potenti
bacteri
pathogen
found
potenti
viral
pathogen
detect
viral
bacteri
pathogen
found
statist
differ
diagnost
yield
exist
standard
filmarray
patient
remain
patient
cap
potenti
pathogen
found
sputum
cultur
obtain
evalu
patient
candid
bacteri
pathogen
found
patient
tabl
pneumonia
identifi
sputa
h
influenza
aureu
cultur
patient
two
patient
bacterem
due
pneumonia
pneumonia
antigen
detect
urin
patient
urin
antigen
test
pneumonia
posit
patient
patient
posit
urin
antigen
test
l
pneumophila
pneumonia
np
pcr
posit
patient
tabl
concomit
urin
antigen
test
posit
aureu
pcr
posit
patient
aureu
also
grew
sputum
cultur
sum
potenti
bacteri
pathogen
detect
cultur
sputum
andor
blood
andor
urin
antigen
andor
pcr
pneumonia
aureu
patient
viral
pcr
panel
detect
respiratori
viru
patient
patient
viru
detect
concomit
bacteri
pathogen
tabl
ad
patient
respiratori
viru
bacteri
pathogen
detect
alon
viru
one
pathogen
identifi
evalu
patient
viral
bacteri
pathogen
identifi
patient
random
standard
panel
patient
random
filmarray
panel
tabl
patient
clinic
syndrom
cap
pathogen
identifi
signific
differ
note
limit
ppmc
viral
diagnost
panel
expand
filmarray
panel
total
number
virus
detect
number
pathogen
distribut
standard
filmarray
patient
present
tabl
influenza
common
viru
detect
either
alon
patient
combin
pneumonia
patient
aureu
patient
pneumonia
without
concomit
viru
found
patient
combin
respiratori
viru
patient
turnaround
time
includ
process
run
result
report
diagnost
test
summar
tabl
filmarray
panel
turnaround
time
mean
hour
compar
ppmc
standard
viral
panel
mean
hour
p
b
urin
antigen
result
report
roughli
hour
nasal
pcr
pneumonia
aureu
approxim
hour
sputum
blood
cultur
result
requir
sever
day
complet
admiss
serum
pct
concentr
summar
fig
pct
level
significantli
lower
patient
infect
viru
versu
patient
infect
bacteria
combin
viru
bacteria
p
b
enrol
evalu
patient
receiv
first
dose
empir
antibiot
therapi
within
six
hour
arriv
leav
ed
lot
dot
cost
antibiot
antivir
influenza
calcul
normal
patientday
tabl
overal
median
cost
therapi
lower
filmarray
patient
versu
standard
patient
vs
p
etiolog
categori
cost
consist
lower
patient
filmarray
group
signific
patient
combin
bacteri
viral
pathogen
p
highest
cost
etiolog
categori
lot
virusonli
patient
significantli
lower
patient
bacteri
infect
p
dot
significantli
lower
filmarray
patient
p
etiolog
categori
identifi
pathogen
dot
consist
lower
filmarray
group
howev
differ
signific
bacteria
viru
patient
p
patient
standard
filmarray
np
pcr
detect
pathogen
viru
without
concomit
bacteri
pathogen
clinic
present
consist
viral
pneumonia
serum
pct
level
ngml
nonetheless
discontinu
empir
antibiot
within
hour
test
result
occur
patient
despit
faster
turnaround
time
filmarray
patient
discontinu
empir
antibiot
almost
ident
filmarray
patient
standard
patient
etiolog
pathogen
detect
evalu
standard
bundl
patient
filmarray
bundl
patient
serum
pct
level
separ
patient
pure
viral
infect
patient
bacteri
mix
viralbacteri
pneumonia
lot
shorter
patient
pure
viral
infect
full
potenti
antibiot
deescal
achiev
contrast
musher
detect
bacteri
pathogen
viral
pathogen
patient
pathogen
found
cap
patient
restrepo
et
al
bacteri
cultur
blood
sputum
plu
urin
antigen
test
l
pneumophila
perform
variou
studi
ad
pcr
probe
atyp
respiratori
pathogen
virus
plu
serolog
report
diagnost
yield
cap
patient
respect
falsey
et
al
jain
et
al
johansson
et
al
shibi
et
al
gadsbi
et
al
collect
sputum
cultur
psi
class
cap
patient
retrospect
pcr
probe
sputa
identifi
one
bacteri
pathogen
patient
respiratori
viru
mixtur
bacteri
viral
pathogen
found
sputa
contain
respiratori
viru
depend
detect
method
use
asymptomat
nasopharyng
colon
healthi
adult
pneumonia
rang
janoff
musher
van
deursen
et
al
approxim
rang
otherwis
healthi
individu
persist
nasal
carrier
aureu
que
moreillon
accept
detect
pneumonia
cultur
urin
antigen
pcr
evid
etiolog
pathogen
oppos
colon
patient
clinic
syndrom
cap
elev
serum
level
procalcitonin
logic
appli
detect
aureu
cultur
nasal
pcr
aureu
interpret
solo
pathogen
patient
aureu
detect
along
either
influenza
hmpv
evalu
patient
posit
blood
cultur
lower
rate
report
said
et
al
similar
report
falsey
et
al
musher
et
al
children
blood
cultur
would
need
collect
identifi
one
bacterem
patient
blood
cultur
limit
psi
class
patient
immunocompromis
cultur
would
need
detect
one
posit
andrew
et
al
summar
tabl
standard
viral
pcr
panel
detect
mani
virusinfect
patient
larger
virus
plu
bacteria
filmarray
panel
suspect
lower
yield
occur
due
low
incid
coronaviru
parainfluenza
chlamydophila
pneumonia
mycoplasma
pneumonia
infect
time
studi
result
demonstr
abil
distinguish
viral
bacteri
infect
within
hour
hospit
admiss
tabl
thu
possibl
reconsid
need
respiratori
isol
antimicrobi
therapi
second
schedul
dose
empir
antibacteri
influenc
rapid
viral
diagnost
serum
pct
level
deescal
absenc
elev
pct
level
patient
clinic
syndrom
compat
viral
ill
strongli
suggest
absenc
activ
bacteri
infect
benefit
empir
antibiot
therapi
becker
et
al
branch
et
al
falsey
et
al
gelfer
et
al
gilbert
gilbert
schuetz
et
al
schuetz
et
al
despit
presenc
respiratori
viral
pathogen
normal
pct
level
empir
antibiot
discontinu
within
hour
patient
studi
oosterheert
et
al
branch
et
al
evalu
patient
hospit
lower
nonpneumon
respiratori
tract
infect
serum
pct
level
ngml
viral
pathogen
detect
result
shorter
durat
antibiot
therapi
p
fewer
patient
discharg
prescript
antibiot
p
studi
patient
major
limit
replic
previou
pilot
studi
evalu
patient
gelfer
et
al
recogn
need
compar
pathogen
detect
pcr
detect
match
control
group
asymptomat
carriag
pneumonia
respiratori
virus
eg
rhinoviru
much
higher
children
adult
self
et
al
henc
detect
adult
appropri
clinic
syndrom
support
pathogen
role
detect
potenti
pathogen
studi
either
suggest
refut
correl
pathogen
densiti
load
invas
diseas
collin
et
al
seroconvers
often
gold
standard
help
acut
ill
albrich
et
al
studi
result
work
other
support
routin
expans
rapid
diagnost
test
bundl
includ
rapid
multiplex
pcr
platform
respiratori
virus
determin
etiolog
cap
fast
turnaround
time
filmarray
offer
quick
assist
antibiot
stewardship
activ
addit
data
support
valu
anterior
nasal
swab
aureu
pcr
np
swab
pneumonia
pcr
test
urin
antigen
pneumonia
l
pneumophila
serogroup
may
ultim
prove
duplic
next
gener
pcr
platform
andor
next
gener
gene
sequenc
sputum
cultur
need
vitro
antimicrobi
suscept
test
challeng
collect
suitabl
specimen
concomit
initi
antibiot
therapi
due
low
yield
blood
cultur
seem
reason
limit
blood
cultur
patient
highest
psi
score
class
low
pct
level
support
absenc
invas
bacteri
diseas
low
pct
level
support
interpret
colon
pneumonia
h
influenza
aureu
potenti
bacteri
pathogen
identifi
